AAPL 174.545 3.0981% MSFT 400.8 -1.3585% GOOG 168.575 -2.9449% GOOGL 166.78 -3.0067% AMZN 180.55 0.5178% NVDA 872.0 -0.6098% META 432.1 -2.5243% TSLA 193.965 15.2564% TSM 137.52 -0.564% LLY 735.26 0.2386% V 272.48 -0.7431% AVGO 1336.05 -0.5967% JPM 193.42 -0.0362% UNH 490.57 -0.965% NVO 127.045 0.1537% WMT 60.075 -0.1413% LVMUY 167.187 -1.2422% XOM 119.54 1.3394% LVMHF 834.7 -1.2014% MA 457.31 -1.1051%
Royalty Pharma plc
Company Overview: Royalty Pharma plc (NASDAQ: RPRX) engages in the acquisition of biopharmaceutical royalties and the provision of financial support for innovation within the biopharmaceutical sector. The company establishes partnerships with pioneers in this field, including those affiliated with academic institutions, research hospitals, and non-profit organizations, extending its reach from small to mid-cap biotechnology firms to large global pharmaceutical corporations.
As per our previous US Daily report published on ‘RPRX’ on 18th September 2023, Kalkine provided an ‘Buy’ stance on the stock at USD 27.77 based on “price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis” and the stock price has now moved by ~4.61% since then.
Noted below are the details of support and resistance levels provided in our previous report:
Xxxxxx Xxxxxx Xxxxxx
Xxxxxx Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx
Xxxxxx Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Enter your details below and our team will help you to decide if this product is best for you.
Kalkine Equities LLC provides general information about companies and their securities. The information contained in the reports, including any recommendations regarding the value of or transactions in any securities, does not take into account any of your investment objectives, financial situation or needs. Kalkine Equities LLC is not registered as an investment adviser in the U.S. with either the federal or state government. Before you make a decision about whether to invest in any securities, you should take into account your own objectives, financial situation and needs and seek independent financial advice. All information in our reports represents our views as at the date of publication and may change without notice.
Kalkine Media LLC, an affiliate of Kalkine Equities LLC, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.
US 
AU
UK
CA
NZ
Please wait processing your request...